WuXi AppTec News & Press Releases - Latest Pharmaceutical Industry Updates

Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results.
Filter By
All Years

2025/08/05

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year

SHANGHAI, August 5, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year. This recognition underscores the Company’s ongoing commitment to sustainable development and its efforts to build a healthier, more sustainable world.

Read more

2025/07/28

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY

(SHANGHAI, July 28, 2025) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first half ending June 30, 2025 (“Reporting Period”).

Read more

2025/07/10

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

Shanghai, July 10, 2025 – WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a Positive Profit Alert for the first half of 2025 and disclosed key operational data forecasts.

Read more

2025/07/07

WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities

Shanghai, July 7, 2025 – WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the status of its A-share repurchase and H-share acquisition activities in Q2 2025.

Read more

2025/07/07

WuXi AppTec Receives MSCI ESG AAA Leader Rating

SHANGHAI, July 7, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its latest annual Environmental, Social, and Governance (ESG) ratings. This is the first time WuXi AppTec has achieved the AAA rating, making it the first A-share listed company in the life science industry to reach this milestone. This achievement underscores WuXi AppTec’s enduring commitment to sustainability and its belief in driving long-term value through responsible growth for a healthier future.

Read more